Article
Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics.
Journal of neuroimmunology - 15 Dec 2014
Berger Thomas, Jacobi Christian, Haas Judith, Ransmayr Gerhard, Guger Michael, Zettl Uwe K, Di Pauli Franziska, Taumberger Birgit, Wietek Stefan, Meuer Stefan, Reindl Markus, Giese Thomas
Abstract excerpt
PURPOSE: Only a fraction of patients do benefit from disease modifying treatments in RRMS and data on IVIG are controversial, it has been suggested that there is a subpopulation of patients with good clinical response to IVIG. METHODS: In the prospective, multicenter, open label, exploratory study RRMS patients receiving IVIG therapy were genotyped and several immune parameters were collected. RESULTS: To...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.